CranioSense | Heinz Ventures Portfolio
CranioSense is a clinical-stage medical technology company developing a non-invasive way to assess and monitor intracranial pressure at the point of care. Its system uses near-infrared optical sensing paired with proprietary algorithms to detect elevated intracranial pressure without the invasive procedures that conventional monitoring requires. The aim is to make intracranial pressure monitoring assessment as routine and accessible as a blood-pressure reading. Heinz Ventures is an investor in CranioSense, and Eric Heinz serves as a business development advisor to the company.
-
Heinz Ventures relationship: Investor
-
Eric Heinz role: Business Development Advisor
-
Sector: Neurotechnology / neurocritical care
-
Stage at investment: Seed
-
Location: Bedford, Massachusetts
Why it fits the Heinz Ventures thesis
Elevated intracranial pressure is a serious, time-sensitive danger across traumatic brain injury, stroke, and other conditions, yet today's gold-standard measurement is invasive enough that it is reserved for the most critical patients. This leaves a majority of cases unmeasured. That gap between clinical need and available instrumentation is exactly the kind of problem where a differentiated, regulated technology can create durable value.
CranioSense fits the thesis on each axis Heinz Ventures looks for: a clear unmet clinical need; differentiated intellectual property in its optical-sensing and algorithm approach; a point-of-care form factor that expands where the assessment can be done; and strategic relevance to established players in neuromonitoring and critical care as the technology reaches clinical milestones.